Last reviewed · How we verify
AZD0585
AZD0585 is a selective activator of the glucokinase enzyme that enhances glucose sensing and insulin secretion in pancreatic beta cells.
AZD0585 is a selective activator of the glucokinase enzyme that enhances glucose sensing and insulin secretion in pancreatic beta cells. Used for Type 2 diabetes mellitus.
At a glance
| Generic name | AZD0585 |
|---|---|
| Also known as | Epanova, Corn oil |
| Sponsor | AstraZeneca |
| Drug class | Glucokinase activator |
| Target | Glucokinase (GCK) |
| Modality | Small molecule |
| Therapeutic area | Diabetes |
| Phase | Phase 3 |
Mechanism of action
Glucokinase is a key glucose sensor in pancreatic beta cells that regulates insulin secretion in response to blood glucose levels. By activating glucokinase, AZD0585 increases the sensitivity of beta cells to glucose, promoting insulin secretion in a glucose-dependent manner. This mechanism aims to improve glycemic control while minimizing hypoglycemia risk since insulin secretion is tied to actual glucose levels.
Approved indications
- Type 2 diabetes mellitus
Common side effects
- Hypoglycemia
- Gastrointestinal disorders
- Headache
Key clinical trials
- AZD0585 Phase III Long-term Study in Japan (PHASE3)
- A Study to Investigate the Effect of Food on Pharmacokinetics of Total EPA and Total DHA of AZD0585 in Healthy Male Japanese Subjects (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- AZD0585 CI brief — competitive landscape report
- AZD0585 updates RSS · CI watch RSS
- AstraZeneca portfolio CI